JP2015515264A - 疾患の処置のためのキメラタンパク質 - Google Patents

疾患の処置のためのキメラタンパク質 Download PDF

Info

Publication number
JP2015515264A
JP2015515264A JP2014561534A JP2014561534A JP2015515264A JP 2015515264 A JP2015515264 A JP 2015515264A JP 2014561534 A JP2014561534 A JP 2014561534A JP 2014561534 A JP2014561534 A JP 2014561534A JP 2015515264 A JP2015515264 A JP 2015515264A
Authority
JP
Japan
Prior art keywords
protein
pathogen
domain
derived
recognition module
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014561534A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015515264A5 (enExample
Inventor
カルル トリグヴァソン，
カルル トリグヴァソン，
ティモ ピカライネン，
ティモ ピカライネン，
ユーハ オヤラ，
ユーハ オヤラ，
ヨナス アクセルソン，
ヨナス アクセルソン，
Original Assignee
スカラテック メディカル アーベー
スカラテック メディカル アーベー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スカラテック メディカル アーベー, スカラテック メディカル アーベー filed Critical スカラテック メディカル アーベー
Publication of JP2015515264A publication Critical patent/JP2015515264A/ja
Publication of JP2015515264A5 publication Critical patent/JP2015515264A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
    • A61M1/3486—Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3823—Affinity chromatography of other types, e.g. avidin, streptavidin or biotin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Anesthesiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
JP2014561534A 2012-03-12 2013-03-12 疾患の処置のためのキメラタンパク質 Pending JP2015515264A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261609523P 2012-03-12 2012-03-12
US61/609,523 2012-03-12
PCT/IB2013/000845 WO2013136180A2 (en) 2012-03-12 2013-03-12 Chimeric proteins for treatment of diseases

Publications (2)

Publication Number Publication Date
JP2015515264A true JP2015515264A (ja) 2015-05-28
JP2015515264A5 JP2015515264A5 (enExample) 2016-04-28

Family

ID=48670612

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014561534A Pending JP2015515264A (ja) 2012-03-12 2013-03-12 疾患の処置のためのキメラタンパク質

Country Status (5)

Country Link
US (1) US20150099297A1 (enExample)
EP (1) EP2825554A2 (enExample)
JP (1) JP2015515264A (enExample)
CN (1) CN104321339A (enExample)
WO (1) WO2013136180A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017075189A1 (en) * 2015-10-27 2017-05-04 University Of Massachusetts Factor h-fc immunotherapy
AU2022426854A1 (en) * 2021-12-31 2024-06-13 The Trustees Of Columbia University In The City Of New York Bispecific molecules to target the first cell
WO2023168292A2 (en) * 2022-03-01 2023-09-07 Hemogenyx Pharmaceuticals Llc Chimeric bait receptors and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005033307A1 (ja) * 2003-09-30 2005-04-14 Kyowa Hakko Kogyo Co., Ltd. 新規のリフォールディング方法およびその方法によって得られたタンパク質
WO2007001332A2 (en) * 2004-08-04 2007-01-04 University Of Massachusetts Anti-pathogen immunoadhesins

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916766A (en) * 1996-05-23 1999-06-29 Smithkline Beecham Corporation Human marco scavenger receptor
WO1998047916A1 (en) * 1997-04-18 1998-10-29 President And Fellows Of Harvard College Bifunctional polypeptides for cell-specific viral targeting
FR2816059B1 (fr) * 2000-10-27 2003-04-11 Pf Medicament Procede d'identification de nouvelles molecules se liant aux recepteurs scavenger et signalees via un recepteur toll
US20060057625A1 (en) * 2002-09-16 2006-03-16 Carlson Robert E Scaffold-based artificial receptors and methods

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005033307A1 (ja) * 2003-09-30 2005-04-14 Kyowa Hakko Kogyo Co., Ltd. 新規のリフォールディング方法およびその方法によって得られたタンパク質
WO2007001332A2 (en) * 2004-08-04 2007-01-04 University Of Massachusetts Anti-pathogen immunoadhesins

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CAO W. ET AL.,: "Oligomerization is required for the activity of recombinant soluble LOX-1.", FEBS J., vol. 276(17), JPN6017003428, 2009, pages 4909 - 4920, ISSN: 0003493105 *
CHEN Y. ET AL.: "A phage display screen and binding studies with acetylated low density lipoprotein provide evidence", J BIOL CHEM., vol. 281(18), JPN6017003420, 2006, pages 12767 - 12775, ISSN: 0003493102 *
JIANG Y. ET AL.: "Identification and Characterization of Murine SCARA5, a Novel Class A Scavenger Receptor That Is Exp", J. BIOL. CHEM., vol. 281(17), JPN6017003430, 2006, pages 11834 - 11845, ISSN: 0003493106 *
MEANS TK ET AL.: "Evolutionarily conserved recognition and innate immunity to fungal pathogens by the scavenger recept", J EXP MED., vol. 206(3), JPN6017003425, 2009, pages 637 - 653, ISSN: 0003493104 *
SANKALA M., ET AL.: "Characterization of recombinant soluble macrophage scavenger receptor MARCO.", J BIOL CHEM., vol. 277(36), JPN6017003422, 2002, pages 33378 - 33385, ISSN: 0003493103 *

Also Published As

Publication number Publication date
EP2825554A2 (en) 2015-01-21
US20150099297A1 (en) 2015-04-09
CN104321339A (zh) 2015-01-28
WO2013136180A3 (en) 2013-12-05
WO2013136180A2 (en) 2013-09-19

Similar Documents

Publication Publication Date Title
Srikrishna et al. Two proteins modulating transendothelial migration of leukocytes recognize novel carboxylated glycans on endothelial cells
Helmerhorst et al. A critical comparison of the hemolytic and fungicidal activities of cationic antimicrobial peptides
KR101997241B1 (ko) 삼중특이성 결합 단백질 및 사용 방법
EA020841B1 (ru) Бифункциональные полипептиды
Ajish et al. A novel hybrid peptide composed of LfcinB6 and KR-12-a4 with enhanced antimicrobial, anti-inflammatory and anti-biofilm activities
US20190037835A1 (en) Method for treating blood, blood products and organs
CN108367048A (zh) 用于组织修复的双特异性治疗性蛋白质
WO2016154491A1 (en) Binding moieties for biofilm remediation
JP2015515264A (ja) 疾患の処置のためのキメラタンパク質
Kohnke-Godt et al. Heparin-binding lectin from human placenta: further characterization of ligand binding and structural properties and its relationship to histones and heparin-binding growth factors
US5962245A (en) Methods for detecting the presence of advanced glycosylation endproducts
WO2019109954A1 (zh) PD-1-Fc融合蛋白及其制备方法和用途
Ebihara et al. Effect of hemoperfusion with polymyxin B-immobilized fiber on plasma endothelin-1 and endothelin-1 mRNA in monocytes from patients with sepsis
CN111018998B (zh) 一种莱姆重组融合蛋白OspC-VlsE及其应用
JP4498444B2 (ja) 抗細菌治療剤
EP3612548B1 (en) Methods for removing bacterial toxins from a biological fluid
JP7449091B2 (ja) 合成化合物
US20190256592A1 (en) Binding agents for use in therapy
CN113557034B (zh) 包含与白蛋白结合的Slit3蛋白的LRRD2的用于预防或治疗骨相关疾病的组合物
US8993518B2 (en) Compositions and methods for treating antiphospholipid syndrome
JP4476934B2 (ja) 新規ペプチドおよび免疫賦活剤、機能性食品ならびに機能性食品の製造方法
Meyer-Hoffert et al. Identification of heparin/heparan sulfate interacting protein as a major broad‐spectrum antimicrobial protein in lung and small intestine
JP5939528B2 (ja) カルモジュリン様皮膚タンパク質を有効成分として含む医薬組成物
WO2012080500A1 (fr) Proteine amyloide p serique
Arystarkhova et al. Immunoaffinity isolation of Na, K-ATPase α3 isoform from pig kidney

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160307

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160307

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170206

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170922